Medivation (MDVN) Tops Q4 EPS by 5c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to Medivation (MDVN) Tops Q4 EPS by 5c, Offers Guidance

Medivation Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Financial Guidance

February 25, 2016 4:10 PM EST

SAN FRANCISCO, CA -- (Marketwired) -- 02/25/16 -- Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the fourth quarter and year ended December 31, 2015.

"We are delighted with our substantial progress in 2015 on many fronts -- marked by strong worldwide net sales of XTANDI (enzalutamide) capsules at the Astellas level, which grew 80 percent over 2014, as well as key developments that enhance the clinical understanding of enzalutamide, expand and diversify our late-stage pipeline, and help secure our plans to continue to meet the needs of underserved patient populations," said David Hung, M.D., founder,... More